Have any questions? 706-721-6582 or cts@augusta.edu
- BHV1510-101 (PBI-410-101): A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of PBI-410 in Participants with Advanced Solid Tumors
Clinical Trial
BHV1510-101 (PBI-410-101): A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of PBI-410 in Participants with Advanced Solid Tumors
This study is phase 1/2 to assess the safety and tolerability of PBI-410 (BHV-1510) alone or in combination with other anti-cancer agents for individuals with advanced solid tumors.
Eligibility Criteria
- Inclusion Criteria: Must be at least 18 years of age. Have an ECOG performance status of 0 or 1 Must have documented unresectable epithelial-origin solid tumor(s) refractory to standard therapies or there are no current therapies. 4.Participants must agree to using highly effective contraceptive methods and avoid egg or sperm donation during the study and up to six months post study. Participants have recovered from acute toxicities from any previous therapies. Exclusion Criteria: Women who are pregnant or lactating. Any clinically significant disease/ malignancy Individual requires supplemental oxygen for daily activities.
RESEARCH. INNOVATION. DISCOVERY.